Mayo Clinic Laboratories > Hematology > Myeloid neoplasms > Acute myeloid leukemia

Acute myeloid leukemia

Results with clinical significance

The presence and pattern of gene mutations in a known or suspected hematologic neoplasm can provide critical diagnostic, prognostic, and therapeutic information for physicians. While many hematologic neoplasms show morphologic or phenotypic similarities, most harbor a distinct composition of somatic gene mutations. Many myeloid neoplasms lack a clonal bone marrow cytogenetic finding at diagnosis (normal karyotype) but can be better characterized with the aid of a comprehensive gene mutation profile.

Fluorescence in situ hybridization Fluorescence in situ hybridization
Fluorescence in situ hybridization

Our comprehensive fluorescence in situ hybridization (FISH) panels simplify the ordering process to ensure every patient receives the right test.

Minimal residual disease Minimal residual disease
Minimal residual disease

Our Molecular Hematopathology Laboratory has developed several minimal residual disease (MRD) evaluations that align with guidelines published by the National Comprehensive Cancer Network and European LeukemiaNet.

Next-generation sequencing Next-generation sequencing
Next-generation sequencing

Our full menu of genetic testing provides the highest quality molecular assays available. Utilization of next-generation sequencing (NGS) in our profiles enables better technical resolution of complex somatic variants.

Clinically validated testing

We strive to provide the highest quality molecular services available to complement your clinical practice by offering a robust menu of clinically validated testing, including:

  • Genetic testing panels, including MayoComplete next-generation sequencing: a comprehensive, 47-gene myeloid neoplasms oncoheme panel and two acute myeloid leukemia (AML)-focused subpanels.
  • A comprehensive, disease-specific menu of fluorescence in situ hybridization (FISH) panels.
  • Molecular analysis that combines reverse transcription, real-time polymerase chain reaction (RT-PCR) technology, and DNA-based fragment analysis to evaluate measurable residual disease (MRD).
News and updates

The latest

NGS for Myeloid Neoplasm Evaluation

In this month's "Hot Topic," David Viswanatha, M.D., discusses updates to Mayo Clinic's next-generation sequencing (NGS) for myeloid neoplasm evaluation, involving new test targets, the rationale for new genetic regions, alignments with the World Health Organization (WHO) guidelines and germline predisposition targets.

Learn more
FISH probe & panel project: An overview

In this month's "Hot Topic," Jess Peterson, M.D., discusses changes to Mayo Clinic Laboratories’ hematology FISH menu to increase awareness, provide reasoning, and highlight some of the great things that are coming.

B-Lymphoblastic Leukemia/Lymphoma [Algorithm]

This algorithm can be viewed here.

INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.